0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Zidovudine-Experienced Patients:  A Randomized Controlled Comparison With Zidovudine Monotherapy

Schlomo Staszewski, MD; Clive Loveday, PhD; Juan J. Picazo, MD; Pierre Dellamonica, MD; Peter Skinhøj, MD; Margaret A. Johnson, MD; Sven A. Danner, MD; P. Richard Harrigan, PhD; Andrew M. Hill; Lucy Verity; Hugh McDade, FRCP
JAMA. 1996;276(2):111-117. doi:10.1001/jama.1996.03540020033026.
Text Size: A A A
Published online

Objective.  —To compare the safety and efficacy of 2 doses of lamivudine given in combination with zidovudine with continued zidovudine monotherapy.

Design.  —Double-blind, randomized, multicenter, comparative trial of 223 patients treated for 24 weeks.

Setting.  —Patients from 32 hospitals in Europe were enrolled throughout a 1-year period.

Patients.  —Adult human immunodeficiency virus type 1 (HIV-1)—positive, zidovudine-experienced (≥24 weeks prior zidovudine) patients with CD4+ cell counts between 0.10 and 0.40×109/L (100-400 cells/μL).

Intervention.  —Patients received either 200 mg of zidovudine every 8 hours, 150 mg of lamivudine every 12 hours plus zidovudine, or 300 mg of lamivudine every 12 hours plus zidovudine for 24 weeks. All patients were then allowed to receive zidovudine and open-label lamivudine combination therapy. Twelve patients withdrew because of adverse events during the 24-week treatment period.

Main Outcome Measures.  —Effcacy was measured by evaluating immunological and viral load changes, and safety was assessed by evaluating clinical manifestations and laboratory indexes of toxic effects.

Results.  —Patients receiving low- or high-dose combination therapy had greater treatment effects compared with patients receiving continued zidovudine monotherapy during the first 24 weeks as documented by changes in CD4+ cell counts (+0.04 vs +0.03 vs −0.02×109/L, respectively; P<.001); log10 HIV-1 RNA as measured by the Roche assay (−0.96 vs −0.77 vs +0.07 copies/mL, respectively; P<.001) or log10 HIV-1 RNA measured by the quantitative nucleic acid sequence— based amplification assay (−0.59 vs −1.06 vs −0.02 copies/mL, respectively; P<.011); and immune-complex dissociated (ICD) p24 antigen (−74% vs −68% vs +27%, respectively; P<.001). There were no statistically significant differences in viral measurements, in CD4+ cell counts, or in safety profile between the groups receiving 2 doses of lamivudine in combination with zidovudine. The effects on CD4+ cell counts and ICD p24 antigen were sustained throughout 48 weeks for patients continuing combination therapy. Patients switching to combination therapy at week 24 showed improvement.

Conclusions.  —In zidovudine-experienced HIV-1—infected patients, combination treatment with lamivudine and zidovudine is well tolerated and provides greater and more sustained increases in CD4+ cell counts and decreases in viral load than continued zidovudine monotherapy.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();